LAMC2 (Laminin subunit gamma-2) variants and mutations
LAMC2 (also known as Laminin subunit gamma-2) is a human protein-coding gene encoding a laminin subunit gamma-2 protein. It contributes the gamma2 chain of laminin-332 and helps anchor epithelial cells to basement membrane through integrin and dystroglycan interactions. Biallelic pathogenic variants cause junctional epidermolysis bullosa with skin and mucosal fragility. This analysis covers 1,627 LAMC2 variants and mutations. Of these, 75% have computational variant effect predictions. Disease context includes Junctional epidermolysis bullosa, Herlitz type, junctional epidermolysis bullosa Herlitz type, and epidermolysis bullosa, junctional 3B, severe. Example LAMC2 variants include M1I, M1T, and M1V.
Variant analysis overview
- Gene: LAMC2
- Protein: Laminin subunit gamma-2
- UniProt accession: Q13753
- Organism: Homo sapiens
- Variants analyzed: 1627
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 1,433 unspecified-consequence records; 106 missense variants; 66 synonymous variants; 11 frameshift variants; 5 stop-gained variants; 4 splice-region variants; 1 protein altering variant; 1 substitution
- Prediction scores: 1,216 variants have prediction scores (75% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Junctional epidermolysis bullosa, Herlitz type, junctional epidermolysis bullosa Herlitz type, epidermolysis bullosa, junctional 3B, severe, epidermolysis bullosa, junctional 3A, intermediate, junctional epidermolysis bullosa, junctional epidermolysis bullosa, non-Herlitz type, Generalized junctional epidermolysis bullosa, non-Herlitz type, junctional epidermolysis bullosa inversa, localized junctional epidermolysis bullosa, non-Herlitz type, eye disorder, atrial fibrillation, acne.
Protein structure and variant hotspots
- Protein features: 10 domains; 6 post-translational modification sites.
- Structural context: 762 variants have structural context.
- PTM context: 7 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable LAMC2 variants
Examples include M1I, M1T, M1V, P2H, P2L, P2T, P2S, P2P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs1479808203, ClinGen CA343662642, ClinVar RCV000665081, MetaLR 0.12, MetaSVM -1.01, Likely pathogenic, Junctional epidermolysis bullosa gravis of Herlitz
- M1T (p.Met1Thr), rs1553262199, ClinGen CA343662631, ClinVar RCV000579075, MetaLR 0.11, MetaSVM -1.00, Pathogenic, not provided
- M1V (p.Met1Val), rs886045625, ClinGen CA10608472, ClinVar RCV000280030, ClinVar RCV000675150, MetaLR 0.11, MetaSVM -1.01, Conflicting interpretations, Epidermolysis bullosa, junctional 3A, intermediate; Epidermolysis bullosa, junct
- P2H (p.Pro2His), ExAC rs780399805, TOPMed rs780399805, gnomAD rs780399805, REVEL 0.09, CADD 23.80
- P2L (p.Pro2Leu), ExAC rs780399805, TOPMed rs780399805, gnomAD rs780399805, REVEL 0.04, CADD 23.80
- P2T (p.Pro2Thr), gnomAD 1-183186356-C-A, REVEL 0.08, CADD 20.50
- P2S (p.Pro2Ser), gnomAD 1-183186356-C-T, REVEL 0.05, CADD 20.70
- P2P (p.Pro2Pro), gnomAD 1-183186358-T-C, CADD 11.50
- A3S (p.Ala3Ser), Ensembl rs1658148101, REVEL 0.05, CADD 21.80
- A3V (p.Ala3Val), TOPMed rs1252714386, gnomAD rs1252714386, REVEL 0.09, CADD 22.50
- A3T (p.Ala3Thr), gnomAD 1-183186359-G-A, REVEL 0.08, CADD 22.50
- A3E (p.Ala3Glu), gnomAD 1-183186360-C-A, REVEL 0.13, CADD 23.60
- A3A (p.Ala3Ala), rs374431798, gnomAD 1-183186361-G-T, CADD 15.70
- L4I (p.Leu4Ile), TOPMed rs1658148481, REVEL 0.06, CADD 22.50
- L4F (p.Leu4Phe), gnomAD 1-183186362-C-T, REVEL 0.10, CADD 24.20
- L4P (p.Leu4Pro), gnomAD 1-183186363-T-C, REVEL 0.06, CADD 22.50
- L4L (p.Leu4Leu), rs1571492931, gnomAD 1-183186364-C-T, CADD 14.80
- W5* (p.Trp5Ter), TOPMed rs1426564374, gnomAD rs1426564374, CADD 40.00, Likely pathogenic
- W5C (p.Trp5Cys), TOPMed rs1426564374, gnomAD rs1426564374, REVEL 0.20, CADD 31.00
- W5L (p.Trp5Leu), gnomAD 1-183186366-G-T, REVEL 0.13, CADD 25.30
- L6L (p.Leu6Leu), gnomAD 1-183186368-C-T, CADD 15.60
- L6M (p.Leu6Met), gnomAD 1-183186368-C-A, REVEL 0.11, CADD 25.50
- L6P (p.Leu6Pro), gnomAD 1-183186369-T-C, REVEL 0.18, CADD 23.20
- G7C (p.Gly7Cys), 1000Genomes rs576076077, ExAC rs576076077, TOPMed rs576076077, gnomAD rs576076077, REVEL 0.17, CADD 12.40, Likely benign
- G7S (p.Gly7Ser), rs576076077, ClinGen CA1282165, ClinVar RCV004410017, 1000Genomes rs576076077, REVEL 0.03, CADD 4.37, Likely benign, Inborn genetic diseases
- G7A (p.Gly7Ala), gnomAD 1-183186369-TG-T, CADD 21.30
- G7V (p.Gly7Val), gnomAD 1-183186372-G-T, REVEL 0.09, CADD 22.70
- G7D (p.Gly7Asp), gnomAD 1-183186372-G-A, REVEL 0.11, CADD 22.50
- G7G (p.Gly7Gly), rs1414927760, gnomAD 1-183186373-C-T, CADD 16.00
- C8Y (p.Cys8Tyr), gnomAD 1-183186375-G-A, REVEL 0.12, CADD 22.90
- C8F (p.Cys8Phe), gnomAD 1-183186375-G-T, REVEL 0.10, CADD 23.00
- C8* (p.Cys8Ter), gnomAD 1-183186376-C-A, CADD 39.00
- C8C (p.Cys8Cys), gnomAD 1-183186376-C-T, CADD 16.10
- C9S (p.Cys9Ser), gnomAD 1-183186377-T-A, REVEL 0.09, CADD 22.40
- C9F (p.Cys9Phe), gnomAD 1-183186378-G-T, REVEL 0.10, CADD 23.70
- C9* (p.Cys9Ter), gnomAD 1-183186379-C-A, CADD 36.00
- L10F (p.Leu10Phe), Ensembl rs1658149509, REVEL 0.09, CADD 23.30
- L10P (p.Leu10Pro), gnomAD 1-183186381-T-C, REVEL 0.22, CADD 26.70
- L10L (p.Leu10Leu), rs772618887, gnomAD 1-183186382-C-T, CADD 8.96
- C11S (p.Cys11Ser), gnomAD 1-183186383-T-A, REVEL 0.05, CADD 11.80
- C11R (p.Cys11Arg), gnomAD 1-183186383-T-C, REVEL 0.09, CADD 15.50
- C11Y (p.Cys11Tyr), gnomAD 1-183186384-G-A, REVEL 0.09, CADD 17.30
- C11F (p.Cys11Phe), gnomAD 1-183186384-G-T, REVEL 0.08, CADD 18.10
- C11C (p.Cys11Cys), gnomAD 1-183186385-C-T, CADD 12.20
- C11* (p.Cys11Ter), gnomAD 1-183186385-C-A, CADD 35.00
- F12V (p.Phe12Val), gnomAD 1-183186386-T-G, REVEL 0.04, CADD 9.53
- F12L (p.Phe12Leu), gnomAD 1-183186388-C-A, REVEL 0.04, CADD 12.10
- F12F (p.Phe12Phe), rs1352517062, gnomAD 1-183186388-C-T, CADD 9.24
- S13L (p.Ser13Leu), rs773517261, NCI-TCGA Cosmic COSV9991, cosmic curated COSV99917, ExAC rs773517261, REVEL 0.06, CADD 12.80, Variant assessed as somatic; moderate impact.
- S13W (p.Ser13Trp), ExAC rs773517261, gnomAD rs773517261, REVEL 0.08, CADD 15.10
- S13* (p.Ser13Ter), gnomAD 1-183186390-C-A, CADD 35.00
- S13S (p.Ser13Ser), gnomAD 1-183186391-G-A, CADD 10.20
- L14F (p.Leu14Phe), gnomAD rs1351893329, REVEL 0.06, CADD 9.70
- L14I (p.Leu14Ile), gnomAD 1-183186392-C-A, REVEL 0.05, CADD 11.20
- L14P (p.Leu14Pro), gnomAD 1-183186393-T-C, REVEL 0.21, CADD 23.40
- L14H (p.Leu14His), gnomAD 1-183186393-T-A, REVEL 0.21, CADD 22.70
- L14L (p.Leu14Leu), rs775148193, gnomAD 1-183186394-C-T, CADD 5.12
- L15F (p.Leu15Phe), cosmic curated COSV51455, ExAC rs762557088, TOPMed rs762557088, gnomAD rs762557088, REVEL 0.12, CADD 20.30
- L15I (p.Leu15Ile), ExAC rs762557088, TOPMed rs762557088, gnomAD rs762557088, REVEL 0.10, CADD 17.70
- L15V (p.Leu15Val), ExAC rs762557088, TOPMed rs762557088, gnomAD rs762557088, REVEL 0.08, CADD 14.80
- L15P (p.Leu15Pro), gnomAD 1-183186396-T-C, REVEL 0.15, CADD 23.20
- L15H (p.Leu15His), gnomAD 1-183186396-T-A, REVEL 0.21, CADD 24.40
- L15L (p.Leu15Leu), gnomAD 1-183186397-C-A, CADD 6.29
- L16M (p.Leu16Met), TOPMed rs911508002
- L16R (p.Leu16Arg), TOPMed rs1658151032
- L16L (p.Leu16Leu), gnomAD 1-183186398-C-T, CADD 11.20
- L16P (p.Leu16Pro), gnomAD 1-183186399-T-C, REVEL 0.23, CADD 22.80
- P17A (p.Pro17Ala), rs1323482086, gnomAD 1-183186398-C-CT, CADD 25.50
- P17S (p.Pro17Ser), gnomAD 1-183186401-C-T, REVEL 0.13, CADD 21.90
- P17T (p.Pro17Thr), gnomAD 1-183186401-C-A, REVEL 0.20, CADD 21.50
- P17L (p.Pro17Leu), gnomAD 1-183186402-C-T, REVEL 0.18, CADD 18.10
- P17P (p.Pro17Pro), rs767456437, gnomAD 1-183186403-C-T, CADD 3.42
- A18S (p.Ala18Ser), Ensembl rs1558075242, REVEL 0.07, CADD 16.10
- A18T (p.Ala18Thr), Ensembl rs1558075242, REVEL 0.05, CADD 18.20
- A18R (p.Ala18Arg), gnomAD 1-183186400-G-GC, CADD 24.40
- A18V (p.Ala18Val), gnomAD 1-183186405-C-T, REVEL 0.06, CADD 17.90
- A18E (p.Ala18Glu), gnomAD 1-183186405-C-A, REVEL 0.15, CADD 16.40
- A19D (p.Ala19Asp), TOPMed rs919996945, gnomAD rs919996945, REVEL 0.15, CADD 14.70
- A19S (p.Ala19Ser), ESP rs367773500, ExAC rs367773500, TOPMed rs367773500, gnomAD rs367773500, REVEL 0.03, CADD 11.70, Uncertain significance, Inborn genetic diseases
- A19T (p.Ala19Thr), gnomAD 1-183186407-G-A, REVEL 0.04, CADD 14.30
- A19V (p.Ala19Val), gnomAD 1-183186408-C-T, REVEL 0.03, CADD 15.30
- A19A (p.Ala19Ala), gnomAD 1-183186409-C-A, CADD 8.66
- R20G (p.Arg20Gly), 1000Genomes rs371296301, ESP rs371296301, ExAC rs371296301, TOPMed rs371296301, REVEL 0.07, CADD 14.70, Uncertain significance
- R20W (p.Arg20Trp), rs371296301, ClinGen CA33934069, ClinVar RCV002799877, 1000Genomes rs371296301, REVEL 0.10, CADD 21.10, Uncertain significance, Inborn genetic diseases
- R20R (p.Arg20Arg), gnomAD 1-183186410-C-A, CADD 9.21
- R20L (p.Arg20Leu), gnomAD 1-183186411-G-T, REVEL 0.08, CADD 11.80
- A21T (p.Ala21Thr), Ensembl rs2102154744, REVEL 0.16, CADD 23.70
- A21S (p.Ala21Ser), gnomAD 1-183186413-G-T, REVEL 0.07, CADD 21.90
- A21V (p.Ala21Val), gnomAD 1-183186414-C-T, REVEL 0.17, CADD 24.00
- A21D (p.Ala21Asp), gnomAD 1-183186414-C-A, REVEL 0.17, CADD 24.20
- A21A (p.Ala21Ala), gnomAD 1-183186415-C-A, CADD 13.80
- T22A (p.Thr22Ala), TOPMed rs1484118529, gnomAD rs1484118529, REVEL 0.09, CADD 23.20
- T22I (p.Thr22Ile), NCI-TCGA Cosmic COSV5145, cosmic curated COSV51458, REVEL 0.04, CADD 22.80, Variant assessed as somatic; moderate impact.
- T22P (p.Thr22Pro), TOPMed rs1484118529, gnomAD rs1484118529, REVEL 0.09, CADD 23.90
- T22T (p.Thr22Thr), gnomAD 1-183186418-C-T, CADD 13.70
- S23T (p.Ser23Thr), NCI-TCGA Cosmic COSV5146, cosmic curated COSV51460, Variant assessed as somatic; moderate impact.
- S23P (p.Ser23Pro), gnomAD 1-183186419-T-C, REVEL 0.17, CADD 24.30
- S23Y (p.Ser23Tyr), gnomAD 1-183186420-C-A, REVEL 0.23, CADD 23.00
- S23S (p.Ser23Ser), gnomAD 1-183186421-C-A, CADD 13.30
- R24G (p.Arg24Gly), ESP rs369305187, ExAC rs369305187, TOPMed rs369305187, gnomAD rs369305187, REVEL 0.03, CADD 9.63, Uncertain significance, Inborn genetic diseases
- R24M (p.Arg24Met), gnomAD 1-183186423-G-T, REVEL 0.11, CADD 22.70
- R24R (p.Arg24Arg), rs755192261, gnomAD 1-183186424-G-A, CADD 15.10
- R24S (p.Arg24Ser), gnomAD 1-183186424-G-T, REVEL 0.13, CADD 23.40
- R25K (p.Arg25Lys), rs1658153097, ClinGen CA343663458, ClinVar RCV003370316, REVEL 0.07, CADD 19.10, Uncertain significance, Inborn genetic diseases
- R25M (p.Arg25Met), TOPMed rs1658153097, REVEL 0.20, CADD 22.40
- R25T (p.Arg25Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R25W (p.Arg25Trp), gnomAD 1-183186425-A-T, REVEL 0.16, CADD 24.10
- R25R (p.Arg25Arg), rs2102154792, gnomAD 1-183186427-G-A, CADD 12.90
- R25S (p.Arg25Ser), gnomAD 1-183186427-G-T, REVEL 0.10, CADD 15.30
- E26* (p.Glu26Ter), TOPMed rs1192849884, gnomAD rs1192849884, CADD 40.00
- E26K (p.Glu26Lys), gnomAD 1-183186428-G-A, REVEL 0.12, CADD 19.50
- E26E (p.Glu26Glu), rs779191964, gnomAD 1-183186430-A-G, CADD 22.70
- E26D (p.Glu26Asp), gnomAD 1-183186430-A-T, REVEL 0.06, CADD 23.50
- V27A (p.Val27Ala), rs772538256, ClinGen CA1282238, ClinVar RCV001096860, ExAC rs772538256, REVEL 0.04, CADD 9.00, Uncertain significance, Junctional epidermolysis bullosa
- V27I (p.Val27Ile), Ensembl rs1168634503
- V27S (p.Val27Ser), gnomAD 1-183186428-GA-G, CADD 25.80
- V27F (p.Val27Phe), gnomAD 1-183186431-G-T, REVEL 0.18, CADD 28.30
- V27V (p.Val27Val), gnomAD 1-183207882-C-T, CADD 0.36
- C28S (p.Cys28Ser), gnomAD 1-183207883-T-A, REVEL 0.97, CADD 27.30
- C28F (p.Cys28Phe), gnomAD 1-183207884-G-T, REVEL 0.96, CADD 26.50
- D29V (p.Asp29Val), Ensembl rs1658944009, REVEL 0.59, CADD 26.30
- D29A (p.Asp29Ala), gnomAD 1-183207887-A-C, REVEL 0.42, CADD 26.50
- D29D (p.Asp29Asp), rs1249729283, gnomAD 1-183207888-T-C, CADD 1.29
- D29E (p.Asp29Glu), gnomAD 1-183207888-T-A, REVEL 0.32, CADD 12.80
- C30G (p.Cys30Gly), ExAC rs766415838, TOPMed rs766415838, gnomAD rs766415838, REVEL 0.98, CADD 26.20
- C30Y (p.Cys30Tyr), 1000Genomes rs142239173, TOPMed rs142239173, REVEL 0.92, CADD 26.60
- C30F (p.Cys30Phe), gnomAD 1-183207890-G-T, REVEL 0.94, CADD 26.80
- C30C (p.Cys30Cys), gnomAD 1-183207891-C-T, CADD 11.10
- N31S (p.Asn31Ser), rs868277253, ClinGen CA33955266, ClinVar RCV003562029, TOPMed rs868277253, REVEL 0.29, CADD 15.10, Uncertain significance, not provided
- G32A (p.Gly32Ala), ExAC rs776609359, gnomAD rs776609359, REVEL 0.60, CADD 25.70
- G32W (p.Gly32Trp), gnomAD 1-183207895-G-T, REVEL 0.75, CADD 28.10
- G32G (p.Gly32Gly), rs151060643, gnomAD 1-183207897-G-A, CADD 6.58
- S34F (p.Ser34Phe), gnomAD rs1473552188, REVEL 0.53, CADD 25.50, Uncertain significance, Inborn genetic diseases
- S34P (p.Ser34Pro), TOPMed rs1658944857
- S34C (p.Ser34Cys), gnomAD 1-183207902-C-G, REVEL 0.52, CADD 24.90
- S34S (p.Ser34Ser), gnomAD 1-183207903-C-A, CADD 8.10
- R35G (p.Arg35Gly), Ensembl rs1558084378, REVEL 0.13, CADD 8.77
- R35K (p.Arg35Lys), TOPMed rs947052612, gnomAD rs947052612, REVEL 0.06, CADD 12.10
- Q36H (p.Gln36His), NCI-TCGA Cosmic COSV5146, cosmic curated COSV51460, Variant assessed as somatic; moderate impact.
- Q36E (p.Gln36Glu), gnomAD 1-183207907-C-G, REVEL 0.20, CADD 8.61
- C37G (p.Cys37Gly), TOPMed rs1658945389, gnomAD rs1658945389, REVEL 0.92, CADD 26.40
- C37Y (p.Cys37Tyr), 1000Genomes rs551090720, REVEL 0.94, CADD 25.40
- I38V (p.Ile38Val), gnomAD rs1156326322, REVEL 0.13, CADD 0.03
- I38N (p.Ile38Asn), gnomAD 1-183207914-T-A, REVEL 0.12, CADD 19.60
- F39F (p.Phe39Phe), gnomAD 1-183207918-T-C, CADD 5.43
- D40E (p.Asp40Glu), NCI-TCGA Cosmic COSV9991, cosmic curated COSV99917, Variant assessed as somatic; moderate impact.
- R41P (p.Arg41Pro), TOPMed rs1658945922, gnomAD rs1658945922, REVEL 0.03, CADD 0.75
- R41Q (p.Arg41Gln), cosmic curated COSV51459, TOPMed rs1658945922, gnomAD rs1658945922, REVEL 0.02, CADD 0.88
- R41W (p.Arg41Trp), cosmic curated COSV99917, gnomAD rs1658945830, REVEL 0.04, CADD 7.83
- E42G (p.Glu42Gly), ExAC rs765078128, gnomAD rs765078128, REVEL 0.20, CADD 24.40
- E42K (p.Glu42Lys), rs1406578480, NCI-TCGA Cosmic COSV9991, cosmic curated COSV99917, gnomAD rs1406578480, REVEL 0.11, CADD 22.50, Variant assessed as somatic; moderate impact.
- E42V (p.Glu42Val), gnomAD 1-183207926-A-T, REVEL 0.28, CADD 25.10
- E42E (p.Glu42Glu), rs1658946280, gnomAD 1-183207927-A-G, CADD 3.73
- H44P (p.His44Pro), TOPMed rs1391397968, gnomAD rs1391397968, REVEL 0.19, CADD 20.90
- H44Q (p.His44Gln), TOPMed rs1450921576, gnomAD rs1450921576, REVEL 0.04, CADD 10.30
- H44R (p.His44Arg), TOPMed rs1391397968, gnomAD rs1391397968
- H44H (p.His44His), gnomAD 1-183207933-C-T, CADD 3.34
- R45G (p.Arg45Gly), rs1333876460, ClinGen CA343669488, ClinVar RCV003008865, gnomAD rs1333876460, REVEL 0.06, CADD 17.50, Uncertain significance, Inborn genetic diseases
- R45K (p.Arg45Lys), NCI-TCGA Cosmic COSV5145, cosmic curated COSV51452, Variant assessed as somatic; moderate impact.
- Q46* (p.Gln46Ter), rs2102196403, ClinGen CA343669964, ClinVar RCV001388079, ClinVar RCV003987858, Pathogenic
- Q46R (p.Gln46Arg), TOPMed rs1268276420, REVEL 0.03, CADD 11.00
- Q46E (p.Gln46Glu), gnomAD 1-183207937-C-G, REVEL 0.10, CADD 3.61
- Q46Q (p.Gln46Gln), rs752996977, gnomAD 1-183207939-A-G, CADD 3.32
- T47A (p.Thr47Ala), ExAC rs763022314, gnomAD rs763022314, REVEL 0.35, CADD 23.40
- G48C (p.Gly48Cys), cosmic curated COSV51452, ExAC rs764250644, TOPMed rs764250644, gnomAD rs764250644
- G48D (p.Gly48Asp), gnomAD rs1658947445, REVEL 0.45, CADD 24.00
- G48R (p.Gly48Arg), ExAC rs764250644, TOPMed rs764250644, gnomAD rs764250644, REVEL 0.52, CADD 24.70
- G48V (p.Gly48Val), gnomAD 1-183207944-G-T, REVEL 0.45, CADD 23.90
- G48G (p.Gly48Gly), gnomAD 1-183207945-T-C, CADD 3.51
- N49D (p.Asn49Asp), ExAC rs765639954, TOPMed rs765639954, gnomAD rs765639954, REVEL 0.08, CADD 8.44
- N49H (p.Asn49His), ExAC rs765639954, TOPMed rs765639954, gnomAD rs765639954, REVEL 0.09, CADD 1.64
- N49K (p.Asn49Lys), 1000Genomes rs569291602, ExAC rs569291602, gnomAD rs569291602, REVEL 0.06, CADD 1.64
- G50E (p.Gly50Glu), Ensembl rs866813818
- G50R (p.Gly50Arg), ExAC rs781646663, gnomAD rs781646663, REVEL 0.35, CADD 25.50
- G50V (p.Gly50Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G50G (p.Gly50Gly), rs1245284627, gnomAD 1-183207951-A-T, CADD 7.19
- F51M (p.Phe51Met), rs1057517353, gnomAD 1-183207945-T-TAA, CADD 16.10
- F51I (p.Phe51Ile), gnomAD 1-183207952-T-A, REVEL 0.19, CADD 17.30
- F51L (p.Phe51Leu), gnomAD 1-183207952-T-C, REVEL 0.07, CADD 16.80
- F51F (p.Phe51Phe), rs376424168, gnomAD 1-183207954-C-T, CADD 9.99
Public LAMC2 analysis runs
- LAMC2 analysis run — LAMC2 (1,627 variants) — completed 2026-08-22